Hematologists Initiating End-of-Life Conversations Too Late

Article

More than half of hematologists providing care to patients with hematologic malignancies reported initiating end-of-life conversations too late in the course of the patient’s disease.

More than half of hematologists providing care to patients with hematologic malignancies reported initiating end-of-life conversations too late in the course of the patient’s disease, according to the results of a survey published in JAMA Internal Medicine.

“Several factors may contribute to untimely end-of-life discussions in hematologic oncology,” wrote Oreofe O. Odejide, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues. “First, unlike most solid malignant neoplasms, which are incurable when they reach an advanced stage (stage IV), many advanced hematologic cancers remain potentially curable. This lack of a clear distinction between the curative and end-of-life phase of disease for many hematologic cancers may delay the initiation of appropriate end-of-life discussions.”

In addition, Odejide and colleagues said that physicians may hesitate to have these discussions for fear of affecting a patient’s ability to cope or their hope for recovery.

According to background material in the study, patients with hematologic malignancies are more likely to undergo treatment and be hospitalized when near death and to die in an acute care setting than patients with solid tumors.

To find out more about when end-of-life discussion are occurring with patients with hematologic malignancies, Odejide and colleagues used a directory from the American Society of Hematology, to conduct a mail survey from September 2014 to January 2015 of 609 hematologists in the United States who provide direct care to patients. The survey asked a series of questions regarding end-of-life discussions and end-of-life care, such as: “In your experience, end-of-life care discussions with patients who have hematologic cancers typically occur…”

Responses were submitted by 57.3% of the hematologists surveyed. The median age of respondents was 52.

More than half of the respondents (55.9%) reported that they thought that end-of-life discussions are typically occurring too late. Specifically, respondents who worked in a tertiary center were significantly more likely to report that these conversations occurred too late than were counterparts who practiced in community centers (64.9% vs 48.7%; P = .003)

The survey also asked about aspects of end-of-life conversations, such as “For patients with life threatening hematologic cancers, when do you typically conduct the initial discussion specifically addressing resuscitation status?”

Results revealed that 42.5% of respondents said that conversations about resuscitation occurred at “less optimal times.” In addition, 23.2% of respondents reported having the initial conversation about hospice care when death is clearly imminent.

Again, hematologists who worked at tertiary centers were found to be less likely to initiate conversations about hospice and resuscitation status at optimal times as compared with hematologists at community centers.

In a commentary about these survey results, Thomas W. LeBlanc, MD, MA, from Duke University School of Medicine in Durham, North Carolina, wrote: “These findings are important. They provide a better sense of hematologic oncologists’ awareness of gaps in the quality of end-of-life care, confirming that hematologic oncologists generally do not have their “heads in the sand” about how they tend to practice. Even more importantly, these findings suggest that hematologic oncologists are uncertain about how to actually change the status quo of end-of-life issues, thereby highlighting a practice gap in need of an intervention. As a practicing hematologic oncologist and a palliative care physician, I believe that the field of hematology should look to specialty palliative care for the answer to this need.”

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Related Content